. 2022 Jan 29;149(4):1242–1252.e12. doi: 10.1016/j.jaci.2022.01.013

Table E2.

Characteristics from 31 individuals fully vaccinated with BNT162b2

Patient ID	Age (years)	Sex	Days after second dose	NT analysis	Total anti-RBD Ig (Wantai)		Anti-S1 IgG (Euroimmun)		Anti-S1 IgA (Euroimmun)
Patient ID	Age (years)	Sex	Days after second dose	NT analysis	Results	RoA	Results	Concentration (BAU∙mL⁻¹)	Results	RoA
A1	25	F	29	Yes	Positive	17.64	Positive	337.88	Positive	0.82
A2	26	M	29	Yes	Positive	17.89	Positive	127.84	Negative	0.55
A3	28	M	29	Yes	Positive	17.82	Positive	203.20	Positive	1.43
A4	28	M	29	Yes	Positive	17.58	Positive	264.62	Negative	0.49
A5	28	F	29	Yes	Positive	17.86	Positive	264.39	Negative	0.50
A6	29	M	29	Yes	Positive	18.15	Positive	162.23	Negative	0.49
A7	30	F	29	Yes	Positive	17.91	Negative	22.90	Negative	0.28
A8	35	M	29	Yes	Positive	18.96	Positive	181.26	Negative	0.61
A9	38	F	29	Yes	Positive	17.66	Positive	189.57	Positive	2.03
A10	39	M	29	Yes	Positive	17.90	Positive	227.50	Positive	0.89
A11	39	M	29	Yes	Positive	18.36	Positive	191.57	Positive	1.46
A12	41	F	29	Yes	Positive	18.35	Positive	173.14	Negative	0.37
A13	42	M	29	Yes	Positive	18.73	Positive	164.09	Positive	1.34
A14	42	M	29	Yes	Positive	19.13	Positive	152.04	Positive	1.55
A15	45	F	29	Yes	Positive	20.24	Positive	373.22	Positive	1.69
A16	47	M	29	Yes	Positive	19.28	Positive	125.39	Negative	0.36
A17	47	F	29	Yes	Positive	17.85	Positive	168.21	Negative	0.60
A18	47	F	29	Yes	Positive	18.67	Positive	453.82	Positive	1.18
A19	50	F	29	Yes	Positive	18.18	Positive	375.76	Negative	0.55
A20	56	F	29	Yes	Positive	18.45	Positive	267.71	Positive	4.44
A21	57	F	29	Yes	Positive	19.20	Positive	318.41	Positive	1.36
A22	58	F	29	Yes	Positive	18.64	Positive	197.86	Negative	0.51
A23	58	F	36	Yes	Positive	17.55	Positive	149.36	Negative	0.26
A24	61	M	36	Yes	Positive	17.92	Positive	358.77	Negative	0.63
A25	62	F	29	Yes	Positive	18.86	Positive	108.98	NA	NA
A26	51	M	29	No	Positive	18.58	Positive	540.93	Positive	6.11
A27	42	M	29	No	Positive	18.81	Positive	259.92	Positive	1.16
A28	56	M	29	No	Positive	18.07	Positive	429.08	Positive	0.82
A29	32	F	29	No	Positive	18.36	Positive	534.19	Positive	2.36
A30	47	F	29	No	Positive	17.86	Positive	423.68	Negative	0.67
A31	51	F	34	No	Positive	19.79	Positive	259.45	Negative	0.51
A32	39	F	33	No	Positive	19.21	Positive	462.21	Positive	2.36
A33	51	F	33	No	Positive	18.27	Positive	350.28	Negative	0.61

Results for total Ig against SARS-CoV-2 RBD and for IgA against SARS-CoV-2 domain S1 are shown as RoA. For IgG against SARS-CoV-2 domain, S1 results are presented in binding antibody units per milliliter of serum (BAU∙mL⁻¹). Serum samples used for the neutralization experiments are indicated in “NT analysis” column. The average age of the participants was 43 years; the percentage of women was 58%. All samples of BNT162b2 vaccinees were taken between 29 and 36 days after the second dose. NA, Not applicable.